ALUPENT
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an inhalation solution small-molecule bronchodilator approved in 1983 by Boehringer Ingelheim. The drug's specific mechanism of action and indications are not detailed in available data, but its inhalation route and formulation suggest respiratory therapeutic use. This is a legacy product with established clinical utility in its indication.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting team consolidation and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALUPENT offers stability in a mature respiratory franchise but limited upside growth potential. Career advancement is best pursued through excellence in managed care, generic defense strategies, and operational efficiency—or by leveraging respiratory expertise toward newer pipeline assets within Boehringer Ingelheim.
Brand ManagerProduct Manager
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.